Skip to main content
. Author manuscript; available in PMC: 2016 Jul 18.
Published in final edited form as: Nat Med. 2016 Jan 18;22(2):146–153. doi: 10.1038/nm.4027

Figure 6. In vivo administration of a mito-ROS scavenger attenuates lupus-like disease in mice.

Figure 6

Effect of 7-week continuous, systemic administration of MitoTEMPO versus vehicle on the phenotype of female MRL/lpr mice (n = 10/ group). (a) Spontaneous NETosis in bone marrow neutrophils at euthanasia quantified by Sytox plate assay in triplicate. (b) Albumin: creatinine ratio at 13 and 17 weeks of age. (c) Anti-dsDNA levels quantified at 15 and 17 weeks of age. IgG (red) and complement C3 (green) deposition in glomeruli of (d) vehicle and (e) MitoTEMPO treated mice harvested at euthanasia. Nuclei were stained blue with Hoechst. (f) Fluorescence intensity scored in renal tissue sections from 8 vehicle- and 8 MitoTEMPO-treated mice. (g) Gene expression in MRL/lpr splenocytes at euthanasia. Results represent mean ± SEM of 10 mice / group and bar graph results represent downregulation adjusted for results found in vehicle-treated mice (normalized to a value of 1). (h) Total and active caspase-1 and IL-18 in renal protein extracts; beta-actin is loading control. Each line depicts an individual mouse treated with either saline or MitoTEMPO as indicated in the figure. Bar graphs show densitometry data for caspase-1 and IL-18 activation ratios. For statistical analysis, unpaired t-test (a, c, f), Mann-Whitney (g, f); * P < 0.05, *** P < 0.001, ****P < 0.0001.